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Tetraploidy constitutes an adaptation to stress and an intermediate step between euploidy and aneuploidy in oncogenesis.
Tetraploid cells are particularly resistant against genotoxic stress including radiotherapy and chemotherapy. Here, we
designed a strategy to preferentially kill tetraploid tumor cells. Depletion of checkpoint kinase-1 (Chk1) by siRNAs, transfection
with dominant-negative Chk1 mutants or pharmacological Chk1 inhibition killed tetraploid colon cancer cells yet had minor
effects on their diploid counterparts. Chk1 inhibition abolished the spindle assembly checkpoint and caused premature and
abnormal mitoses that led to p53 activation and cell death at a higher frequency in tetraploid than in diploid cells. Similarly,
abolition of the spindle checkpoint by knockdown of Bub1, BubR1 or Mad2 induced p53-dependent apoptosis of tetraploid
cells. Chk1 inhibition reversed the cisplatin resistance of tetraploid cells in vitro and in vivo, in xenografted human cancers.
Chk1 inhibition activated p53-regulated transcripts including Puma/BBC3 in tetraploid but not in diploid tumor cells.
Altogether, our results demonstrate that, in tetraploid tumor cells, the inhibition of Chk1 sequentially triggers aberrant
mitosis, p53 activation and Puma/BBC3-dependent mitochondrial apoptosis.
Citation: Vitale I, Galluzzi L, Vivet S, Nanty L, Dessen P, et al (2007) Inhibition of Chk1 Kills Tetraploid Tumor Cells through a p53-Dependent
Pathway. PLoS ONE 2(12): e1337. doi:10.1371/journal.pone.0001337
INTRODUCTION
Cancer results from the accumulation of genetic and epigenetic
alterations in which genomic instability conditions the progressive
deterioration towards an ever more aggressive phenotype. One of
the mechanisms of genomic instability involves a transient phase of
polyploidization (in most cases tetraploidization), which may result
from endoreplication (DNA replication without mitosis), endomi-
tosis (karyokinesis without cytokinesis) [1] or aberrant cell fusion
[2,3]. Tetraploid cells then can undergo asymmetric cell division
and/or chromosome loss, leading to aneuploidization and
chromosomal instability [4–6].
Under normal conditions, a variety of endogenous tumor
suppressor gene products prevent the generation of tetraploid cells.
For instance, p53 is activated immediately after illicit tetraploidi-
zation induced either by fusion [7], endoreplication, or endomi-
tosis [8], and promote cell cycle arrest [9–12] and/or the
activation of pro-apoptotic genes that cause the elimination of
the tetraploid cell by programmed cell death [7,8,12,13].
Inactivation of the p53 pathway is hence permissive for
tetraploidization [6]. Similarly, the loss of the tumor suppressor
proteins p21 [14], Bax [8], APC [15], or Lats2 [12] facilitates the
generation of tetraploid cells. Symmetrically, overexpression of
oncogene products such as Aurora kinase A [16] or papillomavirus
E6 [17] induces tetraploidization. One possible interpretation of
these findings is that a hypothetical ‘‘tetraploidy checkpoint’’ [9]
would prevent the generation or propagation of tetraploid cells, by
mean of a stable cell cycle arrest or their elimination by apoptosis.
Indeed, defective checkpoints have been involved in oncogenesis,
at several levels. As an example, it has been shown that the
activation of Chk2 helps in the elimination of potentially
malignant cells [18,19], and that familial loss-of-function muta-
tions [20] or an acquired interruption of Chk2 activation [18,19]
contribute to oncogenesis. The checkpoint kinase-1 (Chk1) is also
lost in aggressive lymphoid tumors [20]. Nonetheless, Chk1 is
involved not only in tumor suppression, and its inhibition can
sensitize tumor cells to DNA damage [21–24], presumably
because the failure to arrest the cell cycle upon DNA damage is
a lethal event.
Experimental tetraploidization of p53-negative mammary
epithelial cells can be employed as a method to generate
transformed, tumorigenic cells, thus providing a proof-of-principle
that tetraploidization may constitute an important intermediate
step in carcinogenesis [5]. Heterotypic fusion has been described in
vivo, in rodent models, for instance between tumor cells and
infiltrating cells from myeloid origin [25] and may contribute to
the plasticity of cancer. A fusogenic retrovirus can induce the
transformation of human cells in vitro through cell fusion [26].
Accordingly, pre-malignant and malignant tetraploid cells have
been documented in precancerous lesions such as Barret’s
esophagus [27], in pre-invasive lesions of the uterine cervix
[17,28], in laryngeal dysplasia [29], and in chronic ulcerative
colitis dysplasia [30]. The presence of sub-clones of tetraploid/
octoploid cells in human tumors has been correlated with worse
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cell carcinoma of the head and neck [32], and in poorly
differentiated prostate carcinoma [33].
Tetraploid cells are intrinsically resistant against genotoxic stress
mediated by ionizing irradiation or by genotoxic agents used for
anti-cancer chemotherapy, including platinum compounds (such
as cisplatin and oxaliplatin) and topoisomerase inhibitors (such as
camptothecin) [8,25], meaning that tetraploid cells have a high
chance to survive apoptosis-inducing regimes. Since polyploid
tumor cells accumulate in particular areas of the cancerous lesion,
for instance in areas of hypoxia [34], it can be speculated that
tetraploid cells might contribute to chemotherapeutic failure.
Based on these considerations, we wondered whether it might
be possible to design strategies for the destruction of tetraploid
tumor cells. Here, we report that inhibition of one particular
drugable kinase, Chk1, leads to the selective destruction of
tetraploid cancer cells. In addition, we provide an exhaustive
characterization of the pro-apoptotic signal transduction pathway
elicited by Chk1 inhibition.
RESULTS
Aberrant mitoses of tetraploid cells with an intact
spindle assembly checkpoint (SAC)
Recently, we have developed a panel of tetraploid HCT116 and
RKO cell clones that bear exactly twice the normal chromosome
content than their diploid precursors, yet lack any other
discernible numeric or structural chromosomic aberration [8]
[35]. Tetraploid tumor cells exhibit a slightly reduced growth rate,
by about 10%, as compared to their diploid precursors [8], a
finding that prompted us to investigate the rate and efficacy of
mitoses. While there was no difference in the rate of mitotic events
between diploid and tetraploid HCT116 cells, we found a
significantly increased frequency of abnormal mitoses in tetraploid
cells (Fig. 1). Such abnormal mitoses were characterized by
misaligned chromosomes during metaphase, multipolar (mostly
tri- or tetrapolar) metaphases, anaphase bridges and cytokinesis
failure resulting into binucleation (Fig. 1A,C). Among tetraploid,
apparently normal or aberrant metaphases were frequently
characterized by the activation of the spindle assembly checkpoint
(SAC), as indicated by the presence of BubR1 on kinetochores
(Fig. 1B,C). Accordingly, SAC was intact in tetraploid cells,
because, treatment with nocodazole or docetaxel induced similar
percentages of mitotic arrested cells and cell death in tetraploid
and diploid clones (Fig. S1). Videomicroscopy of the nuclear and
cellular divisions of tetraploid cells transfected with a histone H2B-
GFP fusion construct (which allows to visualize chromosomes in
live cells) confirmed that 10 to 15% of tetraploid mitoses were
aberrant (Videos S1, S2), while less than 3% of diploid mitoses
were abnormal.
A fraction of tetraploid cells displayed an activating phosphor-
ylation of p53 (detectable by immunofluorescence using an
antibody that stains p53 phosphorylated on serine 15) within their
nuclei, and these phospho-p53-positive cells were in most cases
(approximately 80%) bi- or multi-nucleated and/or or contained
micronuclei (Fig. 1D,E), suggesting that p53 activation resulted
from mitotic failure. The large majority of mitoses (as discerned by
the presence of mitotic figures after Hoechst 33342 staining) were
phospho-p53-negative. Only in a small percentage of mitoses that
bears features of imminent apoptosis (with clumpy chromatin
condensation), p53 appears to be phosphorylated (not shown). In
contrast normal interphases (G1, S or G2) were mostly (.99%)
negative for phospho-p53. Only cells with abnormal nuclear
morphologies manifested the p53 phosphorylation on Ser15.
The frequency of cells that activated a p53-inducible green
fluorescent protein (GFP) construct was higher among tetraploid
than among diploid cells (Fig. 1F,G). As an internal control that
the p53-inducible GFP indeed detected an elevated p53-mediated
transactivation, we found that inhibition of p53 either chemically
(with cyclic pifithrin-a) or genetically (by transfection with a
dominant-negative p53 mutant) inhibited the production of p53-
inducible GFP in response to cisplatin down to the background
level (Fig. 1G). Altogether, these results suggest that catastrophic
mitoses are responsible for an enhanced activation of the p53
system in tetraploid cells.
Aberrant mitoses of tetraploid cells are exacerbated
by Chk1 inhibition
In view of the apparent difficulty of tetraploid cells to successfully
complete mitosis, we wondered whether these cells might rely more
heavily on the cell cycle checkpoint kinase Chk1 than diploid cells.
Transient transfection with a Chk1-specific small interfering RNA
(siRNA) (Fig. 2A) caused a dramatic increase in aberrant mitoses of
tetraploid cells (one third of all mitoses), resulting in delayed mitotic
exit, apoptotic disintegration of both daughter cells after cytokinesis,
formation of binucleated cells, multipolar mitoses, or apoptosis
during or shortly after the metaphase (Fig. 2B,C,D and videos
S3, S4, S5, S6, S7, S8). This correlated with premature mitoses,
detectable as events in which the phosphorylation of histone H3 by
mitotic kinases occurs in cells that have not duplicated their genome,
and hence have less than 8N DNA content (Fig. 2E,F). The
percentage of premature mitoses was not affected by preincubation
with the pancaspase inhibitor Z-VAD.fmk (not shown). The increase
in frequency of aberrant or premature mitoses induced by Chk1
inhibition was more pronounced among tetraploid than among
diploid cells (Fig. 2A–F).
Chk1 inhibition abolished the spindle assembly
checkpoint (SAC) and activates p53
The knockdown of Chk1 resulted in a complete abolition of SAC
resulting in the failure to recruit BubR1 and Bub1 to kinetochores
during the prometaphase and aberrant metaphases for diploid and
tetraploid cells (Fig. 3A,B for tetraploid cells). Indeed, after Chk1
knockdown less than 30% of prometaphases and aberrant
metaphases exhibited the localization of Bub or BubR1 to
kinetochores, indicating abolition of SAC in more than 70% of the
cells. The percentage of SAC inhibition, as detectable among
aberrant metaphases, was similar in diploid and tetraploid cells
(although the number of aberrant metaphases is much higher in
tetraploid cells, see Fig. 1). Small interfering RNA (siRNA)-mediated
depletion of Chk1 or its pharmacological inhibition by UCN-01 (7-
hydroxystaurosporine) also resulted in the activating phosphoryla-
tion of p53, more frequently in tetraploid than in diploid cells
(Fig. 3C). Similarly, the knockdown of the essential SAC proteins
Bub1, BubR1, Mad2 or Aurora B induced the phosphorylation of
p53 on serine 15, more so in tetraploid than in diploid cells
(Fig. 3D,E). Taken together, these data indicate that Chk1
inhibition abolishes SAC, and that SAC inhibition exacerbates
mitotic defects coupled to p53 activation in tetraploid tumor cells.
Chk1 inhibition kills tetraploid cells
In view of the mitotic or post-mitotic apoptosis induced by Chk1
depletion (Fig. 2A–C), we quantified the frequency of cell death
induced by Chk1 inhibition by cytofluorometric methods.
Simultaneous detection of dying cells (which exhibit a dissipated
mitochondrial transmembrane potential, i.e. DYm, and hence a
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permeabilized plasma membranes and hence incorporate the vital
dye propidium iodide, i.e. PI) revealed that depletion of Chk1 with
either of two distinct siRNAs killed tetraploid HCT116 cells more
efficiently than diploid cells. This effect was less pronounced when
instead of Chk1, Chk2 was depleted (Fig. 4A,B). The downregu-
lationof Chk1wasmoreefficient ininducing anapoptosis-associated
DNA loss (sub-G1 DNA content, as determined by staining with
DAPI) among tetraploid than among diploid cells (Fig. 4C,D).
Similar results were obtained for another colon carcinoma cell line,
namely RKO (Fig. S2 A) in thus far that Chk1 depletion was more
efficient in killing tetraploid than diploid tumor cells.
Figure 1. Abnormal mitoses linked to p53 activation in tetraploid HCT116 cells. A. Abnormal mitoses. Tetraploid cells were stained to visualize
chromosomes (Hoechst 33342, blue) and c-tubulin (green). The arrow marks a misaligned chromosome. B. Activation of the spindle assembly
checkpoint (SAC) in tetraploid mitoses. Cells are stained to visualize chromosomes (blue), centromeres (CENP-B, red) and the SAC protein BubR1
(green). The white color results from the overlap of the three fluorescence signals, indicating recruitment of BubR1 to centromeres. C. Quantitation of
the data obtained in A and B, comparing diploid and tetraploid cells in three independent experiments (X6SEM). D, E. p53 phosphorylation linked to
abnormal mitoses. Representative examples of tetraploid cells that show incomplete cytokinesis, binucleation and micronucleation coupled to p53
phosphorylation on serine 15 (detected by immunofluoresence staining) are shown in D and quantified in E. F, G. Evidence for transcriptional
activation of p53 in tetraploid cells. Diploid or tetraploid cells were transfected with dsRed (red fluorescence), a p53-inducible GFP construct (green
fluorescence), and either empty vector only, a plasmid encoding for wild type p53 or dominant-negative p53 (H175) and then cultured for 48 h in the
absence or presence of the p53 inhibitor cyclic pifithrin-a. Cells were labeled with the vital stain DAPI and the frequency of transfected (dsRed-
expressing) cells that express GFP was determined by cytofluorometry as shown in D for vector-only controls cultured in the absence of pifithrin.
Representative results (X6SEM, n=3) from three independent experiments are shown in E. Asterisks indicate significant (p,0.01) differences
between diploid and tetraploid cells.
doi:10.1371/journal.pone.0001337.g001
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specific siRNAs, we repeated the experiments using alternative
methods of Chk1 inhibition. Transfection with a dominant-
negative (DN) Chk1 mutant (Fig. 5A) or inhibition of Chk1 with
UCN-01 or SD1825 (Fig. 5B–F) resulted in an enhanced
mortality of tetraploid HCT116 cells, with little or no effects on
diploid cell. Efficient cell death of tetraploid cells was confirmed
in RKO cells after pharmacological inhibition of Chk1 (Fig. S2
B). Moreover, alternative strategies to subvert SAC, by
knockdown of Bub1, BubR1, Mad2 or Aurora B caused cell
death much more efficiently in tetraploid than in diploid cancer
cells (Fig. 5G, H).
Figure 2. Effect of Chk1 depletion on mitosis and p53 activation in tetraploid cells. A. Efficient Chk1 depletion after transfection with a specific
siRNA. Tetraploid RKO cells were transfected with a Chk1-specific siRNA (Chk1a) or scrambled (SCR) control siRNA and the abundance of Chk1 was
determined by immunobloting. GAPDH was detected to control equal loading. B–D. Videomicroscopic analyses of tetraploid cell division. Tetraploid
RKO cells stably transfected with a histone H2B-GFP fusion construct (green fluorescence marking chromosomes) were transfected with a Chk1-
specific siRNA (Chk1a) and monitored 48 h later for abnormal mitosis. Representative sequences of pictures in B illustrate normal mitosis (0), delayed
mitotic exit resulting in apparently normal division (I), apoptotic disintegration of daughter cells after cytokinesis (II), abnormal metaphase plates
leading to formation of binucleated cells (III), multipolar mitoses (IV) and apoptosis during or shortly after the metaphase (V). The frequency of mitotic
aberrations observed in cells that were transfected with a control siRNA (SCR) or the Chk1-depleting siRNA was calculated after having monitored 150
to 200 mitoses (C) and the length of mitosis was computed (D). E, F. Premature mitosis in Chk1-depleted tetraploid cells. Thirty-six hours after
transfection with control siRNA (SCR) or Chk1-depleting siRNA, diploid or tetraploid cells were stained to measure DNA content (with DAPI) and
histone H3 phosphorylation, followed by cytofluorometric analysis. The rectangle in E marks the population of cells showing the phosphorylation of
mitotic histone H3. Numbers refer to percentage of diploid or tetraploid cells with less than 4N or 8N, respectively, that manifest premature mitosis.
The quantification is represented in F. (X6SEM, n=3).
doi:10.1371/journal.pone.0001337.g002
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hallmarks of apoptosis such as nuclear DNA condensation
(Fig. 2B), mitochondrial cytochrome c release, caspase-3 activation
(Fig. 5D,E), and phosphatidylserine exposure (Fig. 5F). In
conclusion, tetraploid cells die from apoptosis after catastrophic
mitoses due to SAC inhibition.
Synergistic killing of tetraploid cells by cisplatin plus
Chk1 inhibition
Ascompared to their diploidcounterparts,tetraploidcancer cells are
relatively resistant againstDNAdamaging agentsincluding cisplatin,
both in vitro (Ref. [8], Fig. 6A,B for HCT116 and Fig. S2 C for
RKO) and in vivo (Fig. 6C,D). Although there was no difference in
the growth tumors originating from diploid versus tetraploid
HCT116 cells inoculated into immunodeficient mice (Fig. 6C),
tetraploid tumors responded far less to chemotherapy with cisplatin
than diploidcancers (Fig. 6D). Chk1depletion (Fig. 6A, Fig. S2C) or
inhibition (Fig. 6B) had an additive cytotoxic effecton tetraploid cells
in vitro, in short-term assays. Treatment of tetraploid HCT116
tumors that had been established in xenotransplanted immunode-
ficient mice with a subtoxic dose of UCN-01 had no growth-
inhibitory effect (Fig. 6E). However, the combination of cisplatin
plus UCN-01 had a synergistic anti-cancer effect, which was
particularly pronounced for tetraploid tumors (Fig. 6F). Based on
theseobservations,we decided toexploretheeffectofcisplatin,Chk1
inhibition and the combination of both on the transcriptome of
diploid and tetraploid colon cancer (HCT116) cells. The number of
cisplatin-modulated genes showing a statistically relevant altered
expression (p value,10
25) was higher among diploid than among
tetraploid cells (Fig. 7A,B), correlating with the higher susceptibility
of diploid cells to cisplatin-induced killing (Fig. 6D). In contrast, the
number of genes modulated by Chk1 inhibition was significantly
higher among tetraploid (152 genes) than among diploid cells (20
genes), with only six genes that were modulated in both diploid and
tetraploid cells (Fig. 7A,B), again correlating with the enhanced
killing of tetraploid cells by Chk1 inhibitors. The combination of
cisplatinandChk1inhibitionmodifiedalargepooloftranscriptsthat
were common to tetraploid and diploid cells, with a higher number
of tetraploid- than diploid- specific transcripts (Fig. 7A,B), in
correlation with the particularly dramatic effects of the combined
therapeutic regimen on tetraploid cells in vivo (Fig. 6F).
Mechanisms of the cytotoxic effects of Chk1
inhibition
Close inspection of the microarray data led us to the discovery that
Chk1 inhibition caused the modulation of a particularly elevated
percentage (12.3%) of p53 target genes in tetraploid cells (18 p53
target genes among a total of 146 Chk1-modulated genes) but not
in diploid cells (none among 14 genes). This percentage is higher
than that observed among the set of genes modulated by cisplatin
(7.6%) or cisplatin plus Chk1 inhibitor (7.0%) in both diploid and
tetraploid cells (Fig. 7B, Tables S1). These results corroborate the
observation that Chk1 inhibition causes the activating phosphor-
ylation of p53 (Fig. 3C). To clarify whether the transcription of
p53 target genes is an epiphenomenon or if it is directly
responsible for cell killing by Chk1 inhibition, we depleted p53
Figure 3. Phosphorylation of p53 on serine 15 in response to SAC inhibition. A, B. Abolition of SAC by Chk1 depletion. Tetraploid cells were either
transfected with a scrambled control siRNA (SCR) or with a Chk1-specific siRNA and then subjected 48 h later to immunofluorescence to determine
the centromeric location of BubR1 or Bub1 (as in Fig. 1B) as a sign of SAC activation. Note that depletion of Chk1 fully abolished SAC. C. p53
activation by Chk1 inhibition in diploid versus tetraploid cells. Cells treated with 15 mM cisplatin, a Chk1-depleting siRNA (or its control SCR) or the
Chk1 inhibitor UCN-01 were stained 48 h later to detect p53 phosphorylation on serine 15. Cisplatin treatment was used as an internal positive
control. D. Efficacy of siRNAs directed against SAC proteins, as determined by immunoblot, 48 hours after transfection. E. p53 phosphorylation on
serine 15 after depletion of SAC proteins. (X6SEM, n=3).
doi:10.1371/journal.pone.0001337.g003
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cytotoxic effect of Chk1 depletion (Fig. 8A). Similarly, tetraploid
derivatives of p53
2/2 HCT116 cells, generated as previously
described [8], died significantly less than the p53 proficient
tetraploid cells in response to the knockdown of Chk1 (Fig. 8B)o r
that of Bub1, BubR1, Mad2 or AuroraB (Fig. 8C). In each case,
the inhibition of p53 strongly attenuated the cytotoxic effects of
cisplatin and/or SAC inhibition.
Next, we downregulated a series of p53 target genes that were
strongly induced by Chk1 inhibition in tetraploid cells (Table S1).
Knockdown of the BH3-only protein Puma/BBC3, of the Bcl-2
antagonist Bax, or of the pro-apoptotic transcription factor ATF3
[36] (Fig. S3) attenuated the cytotoxic effect of Chk1 inhibition in
tetraploid cells, while the depletion of villin 3 (ezrin), spermidine/
spermine N1-acetyltransferase (SSAT) or of the essential autoph-
agy gene Atg12 had no such effect (Fig. 8D). These results
suggested that the Bcl-2 protein family dictates the fate of Chk1-
inhibited tetraploid cells. Accordingly, knockdown of Puma/BBC3
and of the pro-apoptotic multi-domain Bcl-2 family proteins Bax
and Bak were as efficient in inhibiting Chk1 depletion-induced cell
death as was the downregulation of p53 and the p53 associated
protein p53BP1 (Fig. 8E). These data could be corroborated at
the genetic level. Tetraploid cells derived from parental Bax
2/2
HCT116, generated as previously described [8], cells failed to die
in response to Chk1 depletion (Fig. 8F). Moreover, knockdown of
the endogenous Bax/Bak antagonists Bcl-2 or Bcl-XL sensitized
tetraploid cells to Chk1 inhibition (Fig. 8E). Altogether, these
results indicate that Chk1 inhibition kills tetraploid cells via the
Figure 4. Apoptosis induction by depletion of Chk1 in tetraploid HCT116 cells. A, B. Loss of the mitochondrial transmembrane potential (DYm)
and viability induced by Chk1 depletion. Diploid (D) or tetraploid (T) cells were transfected with either of two siRNAs specific for Chk1 (Chk1a, Chk1b)
or Chk2 (Chk2a, Chk2b) and stained 48 h later to measure DYm (with DiOC6(3)) and viability (with PI). Representative FACS pictograms are shown in A
and data are quantified in B. C, D. Apoptotic DNA loss induced by Chk1 depletion. Cells were stained with DAPI to measure DNA content, 24, 48 or
72 h after transfection with Chk1-depleting siRNA. Data shown in C have been obtained 48 h after transfection. The numbers in C refer to the
percentage of cells with a sub-G1 DNA content. Inserts in D demonstrate siRNA-mediated Chk1 and Chk2 depletion, as detected by immunoblots.
*p ,0.01 and ** p,0.001 as compared to untreated or control siRNA-transfected (SCR) controls. Data represent the mean of three independent
experiments in triplicate. (X6 SEM).
doi:10.1371/journal.pone.0001337.g004
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PLoS ONE | www.plosone.org 6 December 2007 | Issue 12 | e1337Figure 5. Apoptosis induction by Chk1 or SAC inhibition. A. Chk1 inhibition by a dominant-negative (DN) Chk1 mutant. Diploid or tetraploid
HCT116 cells were transfected with vector only (Co) or vectors encoding wild type (WT) or DN Chk1 or Chk2, together with a DsRed-encoding
construct. 48 h later, cells were stained with DiOC6(3) and the frequency of DiOC6(3)
low cells was determined among the transfected (dsRed
+)
population. B–F. Chk1 inhibition by pharmacological agents. HCT116 cells were cultured for 48 h in the presence of the indicated concentrations of
UCN-01 (B,D) or SD1825 (C,D) and the frequency of dead and dying cells was measured by co-staining with DiOC6(3) and PI (as in Fig. 3A).
Alternatively, cells cultured on polylysin slides were stained for the simultaneous immunofluorescence detection of mitochondrial cytochrome c (Cyt
c) release and caspase-3 activation (Casp-3a). Representative microfluorographs are shown in D and the frequency of cells showing diffuse Cyt c
staining and caspase-3 activation are scored in E. Finally, phosphatidylserine exposure was measured in diploid and tetraploid RKO cells by annexin V-
FITC staining (F). Asterisks denote significant (p,0.01) effects of Chk1 inhibition. G, H. Preferential mortality of tetraploid cells subjected to SAC
inhibition. Diploid or tetraploid cells were depleted from the indicated SAC proteins. Forty-eight hours later, apoptotic events were scored by
measuring the frequency of DYm (with DiOC6(3)) and viability (with PI) (G) or sub-G1 cells (H). Columns represent the average of three independent
experiments 6SEM.
doi:10.1371/journal.pone.0001337.g005
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PLoS ONE | www.plosone.org 7 December 2007 | Issue 12 | e1337Figure 6. Combined effects of Chk1 inhibition and cisplatin on tetraploid tumor cells in vitro and in vivo. A. Cytotoxic effects of Chk1 depletion in
combination with cisplatin. Diploid (D) and tetraploid (T) HCT116 cells were knocked down for Chk1 (or transfected with control siRNA SCR) for 24 h
and then cultured in absence or presence of cisplatin (20 mM) for further 48 h. Finally, the frequency of dying (DiOC6(3)
low PI
2) or dead (DiOC6(3)
low
PI
+) cells was monitored by DiOC6(3)/PI staining. B. Cell killing by pharmacological inhibition of Chk1 plus cisplatin. Cells were cultured with cisplatin
(20 mM), UCN-01 (500 nM) and/or SD1825 (500 nM) for 48 h, and dead and dying cells were determined as in A. C–E. Combined effects of Chk1
inhibition and cisplatin on tetraploid tumors established in vivo. Diploid or tetraploid HCT116 tumors were established in vivo and their growth was
monitored continuously from day 18 (when tumors measured 125 to 250 mm
3), when animals were injected with PBS alone (controls in C), cisplatin
(D), UCN-01 (E), or with a combination of both (F). Asterisks indicate significant differences between diploid and tetraploid cells (p,0.05, unpaired
Student t test). The results shown in Fig. 6C–E are representative for three different experiments.
doi:10.1371/journal.pone.0001337.g006
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membrane permeabilization through the induction of Puma,
which in turn acts on its mitochondrial receptors Bax and Bak.
DISCUSSION
In the present study, we show that inhibition of Chk1 by small
interfering RNAs, dominant-negative mutant Chk1, or pharma-
cological compounds is particularly toxic on tetraploid tumor cells
that otherwise are relatively resistant against genotoxic agents. The
mechanism accounting for the preferential killing of tetraploid cells
appears to involve the abolition of the spindle assembly checkpoint
(SAC), premature entry in mitosis, failed and catastrophic mitotic
events, as well as p53 activation, transcription of pro-apoptotic p53
target genes including the BH3 only protein Puma and induction
of the mitochondrial pathway of apoptosis.
Although this sequence of events is well documented in this paper,
it is at variance with previous knowledge on cell death induction by
Chk1 inhibition. First, Chk1 activation reportedly causes the
phosphorylation of p53, resulting in its stabilization and its
transcriptional activation [37]. On the contrary, here we show that
the inhibition of Chk1 can activate p53, as indicated by an increased
p53 phosphorylation and an increased transcription of p53 target
genes. Second, Chk1 inhibition by UCN-01 or other chemical Chk1
inhibitors has been shown to sensitize preferentially p53-deficient
cells [38–40]. In contrast with this notion, we show here that, at least
for tetraploid cells, p53 activation is required for the cytotoxic effect
of Chk1 inhibition. Thus, inhibition of p53 (chemically or
genetically, by knockdown or knockout) strongly reduced cell killing
by Chk1 inhibition or depletion.
What may be the mechanism through which Chk1 inhibition is
particularly toxic for tetraploid cells? Reportedly, Chk1 is required
Figure 7. Microarray analyses of the transcriptome of diploid (D) and tetraploid (T) HCT116 cells treated with cisplatin, Chk1 inhibitor or the
combination of both. A. Hierarchical cluster analysis of 1411 gene expression profiles in the 6 experimental samples is shown. Each row represents
the combination of two dye-swap experiments compared to untreated control cells and each column represents a single gene. Red and green colors
indicate an increase and a decrease, respectively, in the expression of genes as compared to unstimulated control cells. B. Overview of the
modification of gene expression by cisplatin and Chk1 inhibition in diploid and tetraploid cells (p value,10
25).
doi:10.1371/journal.pone.0001337.g007
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PLoS ONE | www.plosone.org 9 December 2007 | Issue 12 | e1337Figure 8. Involvement of p53 and Bcl-2 family proteins in apoptosis induction by Chk1 inhibition. A. Effect of p53 knockdown. Diploid or
tetraploid HCT116 cells were transfected with control siRNA (SCR), a p53-specific siRNA, and/or Chk1-depleting siRNA and cultured in the presence of
absence of cisplatin during the last 24 hours of the 72-hour experiment. Then, cells were stained with DiOC6(3)/PI. B,C. Effect of p53 knockout.
Tetraploid HCT116 cells generated on a wild type (WT) or p53 knockout (p53
2/2) background were treated with the indicated combination of Chk1-
depleting siRNA and/or cisplatin (B) or were depleted from SAC proteins (C), followed by determination the frequency of dying (DiOC6(3)
low PI
2)o r
dead (DiOC6(3)
low PI
+). Results (X6SEM, n=3) are representative of three independent determinations. Asterisks indicate a significant protection by
p53 deletion. D. Contribution of p53 target genes to Chk1 depletion-induced apoptosis. Tetraploid HCT116 cells were transfected with the indicated
siRNAs and the frequency of cell death was determined by DiOC6(3)/PI staining. E. Contribution of p53 and pro-apoptotic proteins of Bcl-2 family to
the death of HCT116 cells induced by Chk1 depletion. Tetraploid HCT116 cells were subjected to the siRNA-mediated downregulation of Chk1 alone
or together with the indicated gene products, followed by measurement of cell viability with a tetrazolium reduction assay. Negative values indicate
sensitization to the cytotoxicity of Chk1 depletion while positive values indicate protective effects (X6SEM, n=3). F. Effect of Bax knockout.
Tetraploid HCT116 cells generated on a wild type (WT) or Bax knockout (Bax
2/2) background were subjected to Chk1 inhibition, followed by
determination of the frequency of dead and dying cells 48 h later. Results (X6SEM) are representative of three independent determinations.
doi:10.1371/journal.pone.0001337.g008
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of vertebrate cells [41] and avoids the accumulation of DNA
breaks at fragile sites [42]. On theoretical grounds, the replication
of a tetraploid set of chromosomes may be particularly vulnerable
to perturbations, which ultimately results in delayed or incomplete
DNA replication followed by premature and catastrophic mitosis.
Chk1 depletion can favor the premature activation of the Cdk1/
cyclin B1 complex [43], before the completion of the S phase, which
leads to mitotic defects with chromosome misalignment during
metaphase, chromosome lagging during anaphase, and kinetochore
defects within the regions of misaligned/lagging chromosomes [44].
Hence, Chk1 depletion may amplify the natural tendency of
tetraploid cells to die during or shortly after mitosis.
There is an alternative and additional explanation for the
preferential toxicity of Chk1 inhibition on tetraploid cells that is
supported by our data. Chk1 is required for spindle checkpoint
function, both in normal and in taxol-treated cells [45]. As shown
here, tetraploid cells have an intrinsic propensity to undergo
mitotic catastrophe although they have an intact spindle assembly
checkpoint (SAC) and even tend to spontaneously activate SAC.
Chk1 depletion compromises the spindle checkpoint by negatively
affecting the Aurora-B-dependent recruitment of BubR1 to
kinetochores [45]. We have confirmed this finding, showing that
Chk1 inhibition prevents the recruitment of both BubR1 and
Bub1 to the centromeres of tetraploid cells during the prometa-
phase or aberrant metaphases. Moreover, we have found that
inhibition of SAC by depletion of essential SAC proteins (such as
Bub1, BubR1 or Mad2) or inhibition of Aurora-B had similar
effects as Chk1 inhibition, namely a selective toxicity for tetraploid
as compared to diploid cells. The abolition of SAC killed tetraploid
cells through the activation of p53, exactly as this has been
observed for Chk1 inhibition. Chk1 inhibition caused the
abrogation of SAC both in diploid and tetraploid cell lines;
nevertheless, SAC is more frequently activated in untreated
tetraploid cells, correlating with an elevated frequency of
abnormal mitoses. Hence, it appears plausible that Chk1
inhibition kills tetraploid cells through its capacity to abolish
SAC and because tetraploids rely more heavily on an intact SAC
than diploid cells.
Chk1 inhibitors including UCN-01 are being introduced into
clinical trials [24] in combination with genotoxic agents such as
cytarabine (for the treatment of acute myeloid leukemia) [46] or
cisplatin (for the treatment of advanced solid tumors) [47], and
proof has been obtained that UCN-01 can actually inhibit Chk1 in
vivo, in tumor cells [46], although the inhibitor may act on other
kinases including Chk2 and PDK1 as well, at least in vitro.A s
shown here, Chk1 inhibition by UCN-01 sensitizes tetraploid cells
to cisplatin-induced cell death, rendering otherwise chemoresistant
tetraploid tumors amenable to treatment, in vivo, in a model of
xenotransplanted human tumors. The mechanism through which
Chk1 inhibition (by UCN-01 or by two distinct specific siRNAs)
can restore the cisplatin sensitivity of tetraploid cells is elusive.
Based on the microarray data and cytotoxic effects, it appears that
diploid cells are relatively refractory to the apoptosis-inducing and
to the transcriptome-modifying effects of Chk1 inhibition (as
compared to tetraploid cells), while tetraploid cells are relatively
resistant against the cytocidal and transcriptional effect of cisplatin
(as compared to diploid cells). The combination of both cisplatin
and Chk1 inhibition had very similar effects on diploid and
tetraploid cells in thus far that it provoked cell death at a
substantially similar level and regulated a largely overlapping
panel of genes at the transcriptional level. Apparently, p53 target
genes are particularly important in mediating the combined lethal
effect of cisplatin and Chk1 inhibition, both in diploid and
tetraploid cells. The DNA damage-elicited kinase ATR is elicited
by cisplatin [48,49] and may participate in the activation of Chk1,
which in turn mediates the cisplatin-induced cell cycle arrest
[50,51]. Hence, inhibition of Chk1 may subvert a DNA damage-
elicited cell cycle checkpoint, thereby preventing DNA repair and
favoring an apoptotic response.
The challenge for future studies will be to determine whether
other specific Chk1 inhibitors can overcome chemoresistance of
tumor cells in vivo, in suitable preclinical models as well as in
clinical trials. It will be particularly interesting to determine
whether Chk1 inhibitors can be used for the treatment or even for
the prophylaxis of polyploidization-associated neoplasias.
MATERIALS AND METHODS
Cell lines, culture, transfection and siRNA
Tetraploid cells were generated from diploid WT, p53
2/2,
Bax
2/2 (gift from Bert Vogelstein) HCT116 and RKO diploid
precursor as previously described in [8,35]. Diploid or tetraploid
HCT116 cells were grown in McCoy’s 5A medium supplemented
with 10% FCS. RKO clones transfected with the cDNA encoding
H2B-GFP were cultured in the presence of blasticidine (20 mg/
ml). All media and supplements for cell culture were purchased
from Gibco-Invitrogen (Carlsbad, USA). For each experiment at
least three clones diploid and tetraploid were used. Subconfluent
cultures were cultured in the absence or in the presence of cisplatin
(20 mM, Sigma-Aldrich, St. Louis, USA) and/or Chk1 inhibitors
(UCN-01 from the NCI, USA; SD1825, from Servier, Neuilly-sur-
Seine, France, see Fig. S4,I C 50 for recombinant Chk1 in vitro:
29 nM) at indicated concentrations for 24–48 hours, in the
presence or in the absence of the pan-caspase inhibitor Z-valine-
alanine-aspartate- fluoromethyl ketone (Z-VAD-fmk, 100 mM) or
of the p53 inhibitor cyclic pifithrin-a (20 mM). Cells were
transfected with pRc/CMV containing human wild-type p53
(WT) or mutant (H175) p53 (gift of T. Soussi, Institut Curie, Paris,
France) under the control of the cytomegalovirus (CMV) promoter
[52]. Alternatively, cells were transfected with CMV-driven
expression plasmids containing WT or DN Chk1 (kinase dead,
gift by K.K. Khanna) [53], WT or DN Chk2 [54], or a p53-
inducible green fluorescence protein (GFP) plasmid (gift from K.
Wiman, Karolinska Cancer Center, Stockolm, Sweden) [55].
Transfections were performed by adding lipofectamine
TM 2000
(Invitrogen) complexed with plasmid (final concentration: 1 mg/
ml) 24 hours before the addition of cyclic pifithrin-a (15 mM;
Sigma-Aldrich) or cisplatin (20 mM; Sigma-Aldrich). In some
experiments, transfections were performed in the presence of
pDsRed2 vector (0.2 mg/ml; Clontech, Palo Alto, USA) to identify
transfected cells. After additional 48 hours, cells were subjected to
cytofluorometric analysis of viability.
The knock-down of Atg12, ATF3, Aurora B, Bad, Bax a, Bcl-2,
Bcl-XL, Bid, Bub1, BubR1, Chk1, Chk2, Mad2, p53, p53BP1,
PUMA, spermidine/spermine N1-acetyltransferase (SSAT), Sur-
vivin, VDAC1, villin 3 (ezrin), was performed with siRNAs
purchased from Sigma-Proligo (The Woodlands, USA, siRNA
sequences in Table S2); the down-regulation of Bak and Bax was
performed with siRNAs (Hs_BAK_5, Hs_BAX_5 and
Hs_BAX_10 HP Validated siRNAs, respectively) purchased from
Qiagen (Hilden, Germany). As a control, a siRNA specific for
emerin [56] as well as unrelated control siRNAs (scramble, SCR)
were used. Cells were cultured in 12-well plates and transfected at
30–40% confluence by adding HiPerFect (Qiagen, Hilden,
Germany) complexed with siRNA (final concentration: 20nM) as
described previously [57]. 72 h later, the efficiency of transfection
was determined by immunoblot.
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reduction assay
3.5610
3 HCT116 cells were seeded in 100 mlo fM c C o y ’ s5 A
medium in 96-well plates and transfected after 24h, as follows. 2.5
pmol of each siRNA plus 2.5 pmol of Chk-1 specific siRNA or
control siRNA (SCR), dissolved in 10 ml of serum-free, antibiotic-
free, DMEM:F12 (1:1) with L-glutamine but no phenol red were
mixed with 0.5 ml of HiPerFect transfection reagent (Qiagen)
dissolved in 10 ml of the same medium and let stand at room
temperature for 30 min. Thereafter, transfection complexes (20 ml)
were added to the cultures. Transfected cells were maintained for
48 h prior to cell viability assays based on the cleavage of the
tetrazolium salt WST-1 (Roche Diagnostics, Germany).
Staining of live cells, immunofluorescence and
videomicroscopy
For the simultaneous assessment of mitochondrial apoptosis and
plasma membrane permeabilization, live cells were stained with
3,39dihexiloxalocarbocyanine iodide or tetramethylrhodamine
methylester (DiOC6( 3 )4 0 n Mo rT M R M1 5 0 n M ,e m i t t i n gi n
green or in red respectively; Molecular Probes-Invitrogen) which
measure DYm, and propidium iodide (PI, 2 mg/ml, Sigma-Aldrich)
or 49,6-diamidino-2-phenylindole (DAPI, 10 mM, Molecular Probes-
Invitrogen), vital dyes that incorporate only into dead cells), for
30 min at 37uC [58]. Exposure of phosphatidylserine (PS) was
evaluated using annexin V-FITC (Molecular Probes, Invitrogen). For
simultaneous measurement of DNA content and Histone H3
phosphorylation, cells were fixed with ethanol (70% v:v), permeabi-
lized with tween (0.25% v:v) and stained with DAPI (10 mM,
Molecular Probes-Invitrogen) and a rabbit antisera specific for
Histone H3 phosphorylated (Upstate, Lake Placid, USA). Cyto-
fluorometric analyses were performed on a FACS Vantage (Becton
Dickinson,San Jose,USA) equipped with a 70 mm nozzle. Data were
statistically evaluated using Cell Quest software (Becton Dickinson).
Alternatively, for fluorescence microscopy, cells were fixed with
paraformaldehyde (4% w:v) then stained with rabbit antisera
specific for p53 phophorylated on serine 15 (Cell Signaling
Technology Inc., Danvers, USA), and for activated caspase-3
(Casp-3a, Cell Signaling Technology Inc.) or with mouse antisera
specific for cytochrome c (cyt c, BD Biosciences, San Jose, USA),
b-tubulin, or c-tubulin (both from Sigma-Aldrich) [7,59].
To detect Bub1, BubR1 and CENP-B, cells were fixed in 4%
(w/v) paraformaldehyde in PIPES buffer (80 mM PIPES, 5 mM
EGTA, 2 mM MgCl2) and co-imunostained with antibodies that
recognize Bub1 (rabbit polyclonal IgG, Chemicon International,
Temecula, USA), BubR1 (mouse monoclonal antibody, BD
Biosciences) and CENP-B (mouse monoclonal IgG, Santa Cruz
Biotechnology, San Jose, USA) (Vitale et al., 2007).
After the incubation with the primary antibody, slides were incu-
bated with goat anti-rabbit or anti-mouse IgG conjugated to Alexa
568 or to Alexa 488 fluorochrome (Molecular Probes-Invitrogen).
Chromatin was stained with Hoechst 33342 (2 mM, Molecular
Probes-Invitrogen). RKO cells expressing histone H2B-GFP were
cultured in the 35mm glass bottom culture dishes (MatTek
Corporation, Ashland, USA), maintained at a constant tempera-
ture of 37uC in an atmosphere with 5% CO2, and were subjected
to pulsed observations using an LSM 510 laser-scanning confocal
microscope (Zeiss, Oberkochen, Germany).
Quantitation of protein expression
Protein samples were prepared from HCT116 or RKO cells in
lysis buffer. Aliquots of protein extracts (50 mg/lane) were
subjected to immunoblots using antibodies specific for Bcl-2
(Santa Cruz Biotechnology), Bub1 (Chemicon International),
CENP-B (Santa Cruz Biotechnology), BubR1 (BD Biosciences),
Chk1 (Santa Cruz Biotechnology), Chk2 (Upstate), Mad2 (Santa
Cruz Biotechnology), VDAC (anti-porin 31HL, Calbiochem
International, Temecula, USA) and GAPDH (Chemicon, CA)
monitored as loading control.
Microarray analyses
We used Agilent long (60bp) oligonucleotide microarrays and the
dual color analysis method in which probes from specimens and
from the reference are differentially labeled with Cyanine 5 and
Cyanine 3 as described previously (Castedo et al, 2006). We
performed a set of 6 dye swap experiments to compare RNAs
obtained, in each case, from tetraploid and diploid HCT116 cell
lines cultured in the presence of cisplatin, UCN-01 and a
combination of both. In each experiment, the reference was RNAs
from cell lines without treatment. From each of the 6 combined
experiments, signatures (list of accession numbers) at p-value of 10
25
are extracted and annotated with updated databases as Entrez-
Gene. A list of 275 p53 regulated genes are defined in Ingenuity
Pathways Analysis program (by a query of genes for which p53
directly interact with DNA, Ingenuity, Mountain View, USA,
http://www.ingenuity.com/products/pathways_analysis.html).
In vivo model
Athymic nu/nu six-week-old female mice (IGR animal facility)
were inoculated s.c in 200 ml of PBS with 3610
6 diploid or
tetraploid HCT116 cells into the lower flank as previously
described [60]. When tumors reached 125 mm
3, mice received
i.p. either 200 ml of PBS1X, 5mg/kg of cisplatin three times a
week during 3 weeks, UCN-01 (7.5 mg/kg/daily) for 5 consecu-
tive days or a combination of cisplatin plus UCN-01. Tumor
growth was evaluated twice a week using a caliper. The mean of
the tumor volume at each point was normalized in each group to
the mean volume measured at the first injection. All animals were
maintained in specific pathogen-free conditions and all experi-
ments followed the FELASA guidelines.
SUPPORTING INFORMATION
Table S1
Found at: doi:10.1371/journal.pone.0001337.s001 (2.69 MB
DOC)
Table S2
Found at: doi:10.1371/journal.pone.0001337.s002 (0.07 MB
DOC)
Figure S1 Intact SAC in tetraploid HCT116 cells. Diploid (D)
or tetraploid (T) HCT116 cells were left untreated or cultured in
the presence of docetaxel (1 mM) or nocodazole (1 mM) for the
indicated period (24 h in A and C) and subjected to cell cycle
analyses (A, B) by labeling with 4,6-diamidino-2-phenylindole
(DAPI) or stained for the detection of phospho-histone H3, a
histone that is specifically phosphorylated during mitosis (C, D).
Representative FACS data are shown in A and C and quantitative
data (X6SEM, n=3) are shown in B and D. In addition the
toxicity of docetaxel and nocodazole was determined by staining
with DiOC6(3)/PI, yielding information on the frequency of dying
(DiOC6(3)low PI-) or dead (DiOC6(3)low PI+) cells (E)
Found at: doi:10.1371/journal.pone.0001337.s003 (2.88 MB TIF)
Figure S2 Apoptosis induction by depletion or inhibition of
Chk1 in tetraploid RKO cells. A. Chk1 depletion kills tetraploid
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PLoS ONE | www.plosone.org 12 December 2007 | Issue 12 | e1337RKO colon cancer cells. RKO cells were transfected with siRNAs
that deplete Chk1 (Chk1a) or Chk2 (Chk2a), as demonstrated by
the immunoblot performed 48 h after transfection. The frequency
of dying (DYmlow) cells was determined by staining with
tetramethyl rhodamine methylester (TMRM, 150 nM, 15 min).
Asterisks mark significant (p,0.01) effects of Chk1 depletion. B.
Chk1 inhibition by SD1825 kills tetraploid RKO cells. RKO cells
were cultured with the indicated doses of SD1825, and the
frequency of dead and dying cells was measured by simultaneous
staining with DiOC6(3) and PI (as in Fig. 3A) 48 h later. C.
Combined effects of Chk1 inhibition and cisplatin (20 mM) on
tetraploid RKO cells. Diploid or tetraploid RKO cells were
treated by siRNAs targeting emerin (as a negative control),
VDAC1 (as a positive control of apoptosis inhibition), Chk1 or
Chk2, followed by staining with TMRM to measure DYm
dissipation
Found at: doi:10.1371/journal.pone.0001337.s004 (1.49 MB TIF)
Figure S3 The efficacy of the siRNAs specific for Puma, ATF3
and Bax was determined by immunoblot, 48 hours after
transfection of tetraploid HCT116 cells with control scrambled
(SCR) siRNA or the indicated specific siRNAs. The polyclonal
rabbit antibodies specific for Puma, ATF3 and Bax were from Y
ProSci Incorporated, Santa Cruz Biotechnology, and Upstate
Biotechnology, respectively. Equal loading was determined with
anti-actin antibody (monoclonal mouse IgG1 from AbCys)
Found at: doi:10.1371/journal.pone.0001337.s005 (3.69 MB TIF)
Figure S4 Chemical structure of SD 1825 and its IC50 for
recombinant Chk1
Found at: doi:10.1371/journal.pone.0001337.s006 (0.96 MB TIF)
Video S1 Abnormal mitoses in untreated tetraploid RKO cells
expressing histone H2B-GFP. The video shows an example of a
cell that undergoes an apparently normal mitosis, followed by
near-to-complete karyokinesis, furrow regression and formation of
one single binucleate cell, as well as a cell arrested in metaphase
Found at: doi:10.1371/journal.pone.0001337.s007 (1.74 MB AVI)
Video S2 Abnormal mitosis in untreated tetraploid RKO cells
expressing histone H2B-GFP. The video exemplifies an aborted
cell division leading to the formation of a single daughter cell
Found at: doi:10.1371/journal.pone.0001337.s008 (1.53 MB AVI)
Video S3 Normal mitosis in Chk-1 depleted tetraploid RKO
cells expressing histone H2B-GFP. Selected pictures are shown in
Fig. 2A, 0
Found at: doi:10.1371/journal.pone.0001337.s009 (1.10 MB AVI)
Video S4 Delayed mitosis in Chk-1 depleted tetraploid RKO
cells expressing histone H2B-GFP. Selected pictures are shown in
Fig. 2A, I
Found at: doi:10.1371/journal.pone.0001337.s010 (1.15 MB AVI)
Video S5 Delayed mitosis leading to apoptosis of both daughter
cells in Chk-1 depleted tetraploid RKO cells expressing histone
H2B-GFP. Selected pictures are shown in Fig. 2A, II
Found at: doi:10.1371/journal.pone.0001337.s011 (0.61 MB AVI)
Video S6 Aberrant mitosis with an abnormal metaphase plate in
Chk-1 depleted tetraploid RKO cells expressing histone H2B-
GFP. Note that the final result of the process is the generation of
one single binucleated cell. Selected pictures are shown in Fig. 2A,
III
Found at: doi:10.1371/journal.pone.0001337.s012 (1.83 MB AVI)
Video S7 Tripolar mitosis in Chk-1 depleted tetraploid RKO
cells expressing histone H2B-GFP. Selected pictures are shown in
Fig. 2A, IV
Found at: doi:10.1371/journal.pone.0001337.s013 (1.07 MB AVI)
Video S8 Apoptosis during the metaphase of Chk-1 depleted
tetraploid RKO cells expressing histone H2B-GFP. Selected
pictures are shown in Fig. 2A, V
Found at: doi:10.1371/journal.pone.0001337.s014 (1.74 MB AVI)
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